Clinical Trial Update: A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing AK105 plus Anlotinib and CapeOx regimens in unresectable metastatic colorectal cancer; status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Unresectable Metastatic Colorectal Cancer

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Anlotinib (anlotinib)
• Bevacizumab (bevacizumab)
• CAPEOX

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Unresectable Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN